论文部分内容阅读
11月18日,美国FDA要求氟替卡松和沙美特罗干粉吸入剂 (Advair Diskus)、莫特罗富马酸盐干粉吸入剂(Foradil Aerolizer)和沙美特罗昔萘酸酯干粉吸入剂 (Serevent Diskus)的生产厂家更新其药品标签中关于警告和用药指南项下的内容,以提醒医护人员和患者这些药物可能会增加严重哮喘的发生率及病死率。所有这些药品都包含长效支气管扩张药“长效β2肾上腺素增效剂(LABA)”类药物。 LABA类药物通常用于哮喘症状的长期控制和预防:预防成年人和儿童因运动引起的喘鸣(支气管痉
On November 18, the U.S. FDA requested that fluticasone and Advair Diskus, Foradil Aerolizer, and Serevent Diskus inhalers, Of manufacturers update their drug label under Warnings and Drug Guide items to remind healthcare workers and patients that these medications may increase the incidence and mortality of severe asthma. All of these medicines include long-acting bronchodilators “long-acting beta 2-adrenaline synergist (LABA)” drugs. LABA drugs are commonly used for the long-term control and prevention of asthma symptoms: prevention of exercise-induced wheezing in adults and children (bronchospasm